MLTX - MoonLake Immunotherapeutics - Stock Forecast

Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

MLTX is currently covered by 9 analysts with an average price target of $85.97. This is a potential upside of $33.31 (63.25%) from yesterday's end of day stock price of $52.66.

MoonLake Immunotherapeutics's activity chart (see below) currently has 36 price targets and 78 ratings on display. The stock rating distribution of MLTX is 98.11% BUY and 1.89% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 20.09% with an average time for these price targets to be met of 45.89 days.

Highest price target for MLTX is $100, Lowest price target is $66, average price target is $79.38.

Most recent stock forecast was given by RICHARD LAW from GOLDMAN SACHS on 06-Aug-2025. First documented stock forecast 21-Jul-2022.

Currently out of the existing stock ratings of MLTX, 52 are a BUY (98.11%), 1 are a HOLD (1.89%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Buy

$82

$27.61 (50.76%)

$73

13 days ago
(06-Aug-2025)

0/4 (0%)

$29.24 (55.42%)

Buy

$66

$11.61 (21.35%)

$66

3 months 6 days ago
(13-May-2025)

0/13 (0%)

$27.46 (71.25%)

Buy

$100

$45.61 (83.86%)

$100

5 months 23 days ago
(27-Feb-2025)

8/27 (29.63%)

$57.63 (136.02%)

86

Buy

10 months 27 days ago
(23-Sep-2024)

3/7 (42.86%)

$37.82 (94.13%)

35

Buy

$104

$49.61 (91.21%)

$92

1 years 1 months 25 days ago
(25-Jun-2024)

1/12 (8.33%)

$64.3 (161.96%)

96

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is MLTX (MoonLake Immunotherapeutics) average time for price targets to be met?

On average it took 45.89 days on average for the stock forecasts to be realized with a an average price target met ratio 20.09

Which analyst has the current highest performing score on MLTX (MoonLake Immunotherapeutics) with a proven track record?

RAGHURAM SELVARAJU

Which analyst has the current lower performing score on MLTX (MoonLake Immunotherapeutics) with a proven track record?

RICHARD LAW

Which analyst has the most public recommendations on MLTX (MoonLake Immunotherapeutics)?

Raghuram Selvaraju has 3 price targets and 19 ratings on MLTX

Which analyst is the currently most bullish on MLTX (MoonLake Immunotherapeutics)?

Andreas Argyrides with highest potential upside - $49.61

Which analyst is the currently most reserved on MLTX (MoonLake Immunotherapeutics)?

Prakhar Agrawal with lowest potential downside - -$0

MoonLake Immunotherapeutics in the News

Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment

MoonLake Immunotherapeutics (NASDAQ:MLTX) is one of the 10 Stocks with Huge Catalysts on the Horizon. The company speeds up the clinical momentum with phase 3 trials, expanded indications, and upcoming data readouts.Phase 3 Trials Accelerate MoonLake Advances for Immunologic Disease Treatment A close-up of a biopharmaceutical research laboratory, with a microscope in the foreground. MoonLake...

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?